Evidence map›Paper›PMID 39902875›Full record

ArticleJournal of clinical microbiology2025

Development and evaluation of a next-generation sequencing methodology for measles virus using Oxford Nanopore Technology.

Vanessa Zubach, Gurasis Osahan, Kurt Kolsun, Claudia Pfeifer, Alberto Severini, Joanne Hiebert

Abstract readEvaluation Study
In one paragraph

Article in Journal of clinical microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Measles vaccine virus mutation following vaccination in a healthy child resulting in a false negative vaccine specific PCR test: Ontario, Canada, 2025.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Vanessa ZubachMeasles, mumps and rubella Unit, National Microbiology Laboratory, Public Health Agency of Canada, JC Wilt infectious Diseases Research Centre, Winnipeg, Manitoba, Canada.ORCID 0000-0001-8513-9973
Gurasis OsahanMeasles, mumps and rubella Unit, National Microbiology Laboratory, Public Health Agency of Canada, JC Wilt infectious Diseases Research Centre, Winnipeg, Manitoba, Canada.
Kurt KolsunMeasles, mumps and rubella Unit, National Microbiology Laboratory, Public Health Agency of Canada, JC Wilt infectious Diseases Research Centre, Winnipeg, Manitoba, Canada.
Claudia PfeiferMeasles, mumps and rubella Unit, National Microbiology Laboratory, Public Health Agency of Canada, JC Wilt infectious Diseases Research Centre, Winnipeg, Manitoba, Canada.
Alberto SeveriniDepartment of Medical Microbiology and Infectious Diseases, Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
Joanne HiebertMeasles, mumps and rubella Unit, National Microbiology Laboratory, Public Health Agency of Canada, JC Wilt infectious Diseases Research Centre, Winnipeg, Manitoba, Canada.ORCID 0000-0003-3238-1859

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report the development of a bench protocol and evaluation of bioinformatics pipelines for the whole genome sequence (WGS) of measles virus (MeV) genotype D8. We established a bench protocol using 1 kb amplicons tiling the MeV WGS. Four different pipeline parameters were assessed based on two basecallers and two quality thresholds: Guppy simplex with Q-score thresholds of 20 and 25 (G20 and G25), and Dorado duplex with Q-score thresholds of 20 and 25 (D20 and D25). Using a reference genome, we determined that complete genomes were obtained down to 10 copies/µL with all four parameters; however, errors began to be detected in the consensus sequence at 100 copies/µL. A panel of specimens from 32 measles cases, for which measles WGS had been obtained by other methods (reference sequences), was used to assess the utility and accuracy of the Oxford Nanopore Technologies (ONT) for the purposes of measles surveillance. We found that a crossing point (Cp) value of 31 (corresponding to approximately 100 copies/µL) or less could be considered a predictor for the generation of accurate and complete WGS. The GQ20 parameter achieved the most complete genomes (75%) and had the most identical sequences (84.4%). Error rates compared with the reference sequences for all parameters were below one nucleotide per whole genome. After assessing the reproducibility, GQ20 had the most identical sequences (97.4%). Finally, we inserted ONT-generated WGS and reference sequences into outbreaks with known epidemiological links, and our results show that the ONT WGS matches the epidemiological data. This evaluation establishes that NGS generated by ONT produces accurate and reliable MeV WGS.IMPORTANCEThe use of ONT-sequencing platforms has the potential to expand the availability of measles sequencing as a result of its relatively lower cost and portability. This study establishes that measles sequences generated by ONT are accurate and reliable. This will enable sequencing in global regions where there is a lack of sequence data (which also tend to be the measles exporting regions) and more timely sequencing in low incidence settings, due also to the lower number of samples needed for the ONT platform. More timely generation of these data enables better investigation of cases, which informs public health response and outbreak management in measles-eliminated countries.

Indexed as

High-Throughput Nucleotide SequencingMeaslesMeasles virusNanopore SequencingWhole Genome SequencingComputational BiologyGenome, ViralGenotypeHumansmeaslesNanoporewhole genome sequence

Identifiers

PMID39902875
PMCPMC11898632

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.